{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:42:16Z","timestamp":1786372936653,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"name":"Innovative Science and Technology Initiative for Security","award":["JPJ004596"],"award-info":[{"award-number":["JPJ004596"]}]},{"DOI":"10.13039\/501100008884","name":"Nakatani Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008884","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,2]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n High intact fibroblast growth hormone 23 levels, measured by automated chemiluminescent enzyme immunoassay, were associated with composite kidney outcomes in non\u2013dialysis-dependent CKD.<\/jats:p>\n <\/jats:list-item>\n \n The association between intact fibroblast growth hormone 23 levels and outcomes was more pronounced in patients with low 24-hour urinary phosphate excretion.<\/jats:p>\n <\/jats:list-item>\n \n Fibroblast growth hormone 23 with 24-hour urinary phosphate excretion may assist in predicting the progression of CKD.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Association between fibroblast growth hormone 23 (FGF23) levels and kidney outcomes and the effect of urinary phosphate excretion (UPE) on this association remain uncertain. This study aimed to investigate the association between FGF23 levels and kidney outcomes on the basis of UPE levels.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This observational study included 946 patients with non\u2013dialysis-dependent CKD at a tertiary medical center in Japan. Intact FGF23 (iFGF23) levels were measured using an automated chemiluminescent enzyme immunoassay. The association between iFGF23 levels and composite kidney failure with replacement therapy and a 40% decline in eGFR was investigated using Cox regression analysis. A nonlinear relationship was investigated using restricted cubic spline analysis. Subgroup analyses on the basis of 24-hour UPE and fractional excretion of phosphate were also performed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The median eGFR level was 46 ml\/min per 1.73 m\n 2<\/jats:sup>\n . During a median follow-up period of 27.2 months, 181 patients experienced composite kidney outcomes. Multivariable Cox regression analysis showed that the risk of composite kidney outcomes was higher in the highest FGF23 category of quartile 4 compared with that in a reference category of quartile 1, with a hazard ratio of 2.12 (95% confidence interval: 1.05 to 4.28). Restricted cubic spline analysis yielded consistent results. The association between high FGF23 levels and composite kidney outcomes was more pronounced in patients with low 24-hour UPE levels. However, fractional excretion of phosphate did not modify this association.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n High iFGF23 levels are associated with composite kidney outcomes in patients with non\u2013dialysis-dependent CKD. This association was more pronounced in those with low 24-hour UPE levels.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.0000000870","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:00:15Z","timestamp":1762448415000},"page":"201-210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-2263","authenticated-orcid":false,"given":"Takaaki","family":"Kosugi","sequence":"first","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8422-7314","authenticated-orcid":false,"given":"Masahiro","family":"Eriguchi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riri","family":"Furuyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9242-4980","authenticated-orcid":false,"given":"Mari","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"V-iCliniX Laboratory, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Tasaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2063-781X","authenticated-orcid":false,"given":"Masatoshi","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-7314","authenticated-orcid":false,"given":"Kaori","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1862-8640","authenticated-orcid":false,"given":"Keisuke","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Samejima","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-3571","authenticated-orcid":false,"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-2928","authenticated-orcid":false,"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"10225","key":"B1-20260318","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"395","year":"2020","journal-title":"Lancet."},{"issue":"1","key":"B2-20260318","first-page":"1","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone Disorder (CKd-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl (2011)."},{"issue":"1","key":"B3-20260318","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol Rev."},{"issue":"12","key":"B4-20260318","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"issue":"5","key":"B5-20260318","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2215\/CJN.08680811","article-title":"Combined use of vitamin D status and FGF23 for risk stratification of renal outcome","volume":"7","author":"Nakano","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B6-20260318","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ki.2009.466","article-title":"FGF23-parathyroid interaction: implications in chronic kidney disease","volume":"77","author":"Komaba","year":"2010","journal-title":"Kidney Int."},{"issue":"11","key":"B7-20260318","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest."},{"issue":"23","key":"B8-20260318","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA."},{"issue":"10","key":"B9-20260318","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B10-20260318","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","article-title":"FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment","volume":"25","author":"Seiler","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"B11-20260318","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2017070772","article-title":"Longitudinal FGF23 trajectories and mortality in patients with CKD","volume":"29","author":"Isakova","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B12-20260318","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B13-20260318","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1053\/j.ajkd.2019.09.009","article-title":"Serial fibroblast growth factor 23 measurements and risk of requirement for kidney replacement therapy: the CRIC (chronic renal insufficiency cohort) study","volume":"75","author":"Mehta","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"16","key":"B14-20260318","doi-asserted-by":"crossref","first-page":"e145693","DOI":"10.1172\/JCI145693","article-title":"Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression","volume":"131","author":"Shiizaki","year":"2021","journal-title":"J Clin Invest."},{"issue":"1","key":"B15-20260318","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1681\/ASN.2014020218","article-title":"Serum fibroblast growth factor-23 is associated with incident kidney disease","volume":"26","author":"Rebholz","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B16-20260318","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000488361","article-title":"Fibroblast growth factor 23: a biomarker of kidney function decline","volume":"47","author":"Drew","year":"2018","journal-title":"Am J Nephrol."},{"issue":"9","key":"B17-20260318","doi-asserted-by":"crossref","first-page":"e1236","DOI":"10.34067\/KID.0000000000000172","article-title":"Associations of FGF23 with 10-year change in eGFR and UACR and with incident CKD in the CARDIA cohort","volume":"4","author":"Sunderraj","year":"2023","journal-title":"Kidney360."},{"issue":"1","key":"B18-20260318","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2215\/CJN.06190614","article-title":"Fibroblast growth factor 23 and incident CKD in type 2 diabetes","volume":"10","author":"Isakova","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B19-20260318","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.2012090894","article-title":"Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes","volume":"24","author":"Dominguez","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B20-20260318","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2215\/CJN.00390118","article-title":"Twenty-four-hour urine phosphorus as a biomarker of dietary phosphorus intake and absorption in CKD: a secondary analysis from a controlled diet balance study","volume":"13","author":"Stremke","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"B21-20260318","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.2215\/CJN.11181012","article-title":"24-hour urine phosphorus excretion and mortality and cardiovascular events","volume":"8","author":"Palomino","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B22-20260318","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B23-20260318","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00774-011-0306-4","article-title":"Evaluation of a new automated chemiluminescence immunoassay for FGF23","volume":"30","author":"Shimizu","year":"2012","journal-title":"J Bone Miner Metab."},{"issue":"11","key":"B24-20260318","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"B25-20260318","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00774-021-01258-7","article-title":"Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system","volume":"40","author":"Kato","year":"2022","journal-title":"J Bone Miner Metab."},{"issue":"4","key":"B26-20260318","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MNH.0000000000000793","article-title":"Contribution of phosphate and FGF23 to CKD progression","volume":"31","author":"Jansson","year":"2022","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"15","key":"B27-20260318","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"2","key":"B28-20260318","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"B29-20260318","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2215\/CJN.04530418","article-title":"Effects of dapagliflozin on circulating markers of phosphate homeostasis","volume":"14","author":"de Jong","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B30-20260318","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int."},{"issue":"4","key":"B31-20260318","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40620-015-0178-0","article-title":"Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients","volume":"28","author":"Bech","year":"2015","journal-title":"J Nephrol."},{"issue":"1","key":"B32-20260318","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40620-022-01358-1","article-title":"Association of combined fractional excretion of phosphate and FGF23 with heart failure and cardiovascular events in moderate and advanced renal disease","volume":"36","author":"Mendon\u00e7a","year":"2023","journal-title":"J Nephrol."},{"issue":"4","key":"B33-20260318","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/ndt\/gfl718","article-title":"Mineral metabolism parameters throughout chronic kidney disease stages 1\u20135--achievement of K\/DOQI target ranges","volume":"22","author":"Craver","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"B34-20260318","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00223-022-00987-9","article-title":"The measurement and interpretation of fibroblast growth factor 23 (FGF23) concentrations","volume":"112","author":"Heijboer","year":"2023","journal-title":"Calcif Tissue Int."},{"issue":"1","key":"B35-20260318","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ejhf.2393","article-title":"Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study","volume":"24","author":"Alnuwaysir","year":"2022","journal-title":"Eur J Heart Fail."},{"issue":"6","key":"B36-20260318","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/ejcn.2016.247","article-title":"Habitual dietary phosphorus intake and urinary excretion in chronic kidney disease patients: a 3-day observational study","volume":"71","author":"Salomo","year":"2017","journal-title":"Eur J Clin Nutr."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:14Z","timestamp":1786369214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000870","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"2025-04-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}